What's in Wyeth is now a wholly owned subsidiary of Pfizer's pipeline?

Wyeth is now a wholly owned subsidiary of Pfizer has 78 drugs in our index: 31 marketed, 0 filed, 17 in Phase 3, 13 in Phase 2, 16 in Phase 1.

Which companies overlap with Wyeth is now a wholly owned subsidiary of Pfizer's portfolio?

Top competitors by shared drug class: Pfizer, National Taiwan University Hospital, Novartis, Massachusetts General Hospital, Eli Lilly and Company.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/wyeth-is-now-a-wholly-owned-subsidiary-of-pfizer.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Wyeth is now a wholly owned subsidiary of Pfizer — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Wyeth is now a wholly owned subsidiary of Pfizer pipeline: 31 marketed, 0 filed, 17 Phase 3, 13 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

31 marketed 0 filed 17 Phase 3 13 Phase 2 16 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Methotrexate plus ENBREL or ENBREL alone	Methotrexate plus ENBREL or ENBREL alone	marketed
Rapamune® (Sirolimus)	Rapamune® (Sirolimus)	marketed	mTOR inhibitor	mTOR (mammalian target of rapamycin)	Immunology
Advante	Advante	marketed			Other
pneumococcus conjugate vaccine	pneumococcus conjugate vaccine	marketed
Third generation cephalosporins	Third generation cephalosporins	marketed	Beta-lactam antibiotic (cephalosporin)	Penicillin-binding proteins (PBPs)	Infectious Disease
ibuprofen Formulation 2	ibuprofen Formulation 2	marketed
ibuprofen Formulation 1	ibuprofen Formulation 1	marketed
Totelle®	Totelle®	marketed
Effexor® (Venlafaxine)	Effexor® (Venlafaxine)	marketed	Serotonin-norepinephrine reuptake inhibitor (SNRI)	Serotonin transporter (SERT); Norepinephrine transporter (NET)	Psychiatry / Neurology
Rapamune	Rapamune	marketed		Peptidyl-prolyl cis-trans isomerase FKBP3, Sodium/nucleoside cotransporter 1, ATP-binding cassette sub-family G member 2	Oncology
7-valent pneumococcal conjugate vaccine	7-valent pneumococcal conjugate vaccine	marketed
Etanercept + Methotrexate	Etanercept + Methotrexate	marketed	TNF inhibitor + DMARD combination	TNF-alpha receptor (etanercept); dihydrofolate reductase (methotrexate)	Immunology

Therapeutic area mix

Immunology · 5
Hematology · 4
Other · 4
Immunology / Infectious Disease · 3
Oncology · 3
Infectious Disease · 2
Gastroenterology / Immunology · 1
Gastroenterology · 1
Contraception / Gynecology · 1
Endocrinology / Menopause · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Pfizer · 8 shared drug classes
National Taiwan University Hospital · 5 shared drug classes
Novartis · 4 shared drug classes
Massachusetts General Hospital · 4 shared drug classes
Eli Lilly and Company · 4 shared drug classes
AstraZeneca · 4 shared drug classes
Hoffmann-La Roche · 4 shared drug classes
Assistance Publique - Hôpitaux de Paris · 3 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Wyeth is now a wholly owned subsidiary of Pfizer:

Cite this brief

Drug Landscape (2026). Wyeth is now a wholly owned subsidiary of Pfizer — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/wyeth-is-now-a-wholly-owned-subsidiary-of-pfizer. Accessed 2026-05-17.